Physician profile
Muhammad Salim
NPI 1205042579
$697.67
in general payments reported to CMS, 2019-2025
16 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $22.78 · 2021: $15.05 · 2022: $23.76 · 2023: $138 · 2024: $238 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $510 · Education: $0.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $510.23 |
| Education | $0.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $123.73 | 2023-2024 | Ubrelvy, Qulipta |
| Sunovion Pharmaceuticals INC. | $109.92 | 2019 | |
| Ucb, INC. | $109.19 | 2024-2025 | Briviact |
| Neurocrine Biosciences, INC. | $75.92 | 2024-2025 | Ingrezza |
| Neurelis, INC. | $55.44 | 2021-2025 | Valtoco |
| Genentech USA, INC. | $25.71 | 2023 | Ocrevus |
| Teva Pharmaceuticals USA, INC. | $24.66 | 2024 | Austedo Xr |
| Argenx US, INC. | $24.56 | 2023 | Vyvgart |
| Pfizer INC. | $23.70 | 2024 | |
| Akcea Therapeutics, INC. | $22.78 | 2020 | |
| Alexion Pharmaceuticals, INC. | $22.06 | 2023 | Ultomiris |
| Eisai INC. | $20.91 | 2025 | |
| Merck Sharp & Dohme LLC | $19.40 | 2024 | Bridion |
| Livanova USA, INC. | $15.58 | 2019 | |
| Allergan, INC. | $15.11 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $9.00 | 2022-2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Salim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.